We compared the immunogenicity of two vaccination schedules with either a systemic or a mucosal booster, both following a mucosal primary vaccination with a recombinant outer membrane fusion protein of Pseudomonas aeruginosa (OprF-I) in 12 healthy volunteers. The systemic booster induced higher levels of OprF-I-specific serum antibodies of IgG isotype, with a mean±S.E.M. of 32.6±7.8×107 enzyme-linked immunosorbent assay (ELISA) units (EU) as compared to the nasal booster with 14.6±2.1×107 EU (P=0.05). Specific serum IgA antibodies and antibodies in saliva did not differ between the two vaccination groups. We conclude that a combined mucosal/systemic vaccination with the OprF-I vaccine may offer an enhanced systemic immunogenicity. Further studies on the long-term immunogenicity and induction of antibodies on the respiratory airway surface are warranted. © 2003 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.
Göcke, K., Baumann, U., Hagemann, H., Gabelsberger, J., Hahn, H., Freihorst, J., & Von Specht, B. U. (2003). Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: Comparison of a systemic vs. a mucosal booster schedule. FEMS Immunology and Medical Microbiology, 37(2–3), 167–171. https://doi.org/10.1016/S0928-8244(03)00094-4